Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

355
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
355
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

243
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
243
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

195
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
195
Actuarial Approach01:20

Actuarial Approach

79
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
79
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

149
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
149

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Local Recurrence and Metastasis Define Distinct Recurrence Phenotypes in Soft Tissue Sarcoma.

Cancers·2026
Same author

3D Deep Learning for Brain Tumor Segmentation and Survival Prediction: A Comprehensive Multi-Modal Analysis Using the BraTS2020 Dataset.

Journal of imaging·2026
Same author

Value operating system: a practical framework to measure outcomes-per-cost at the episode level.

BMJ open quality·2026
Same author

Twelve-Month Metastatic State as a Landmark-Based Prognostic Stratifier in Metastatic Sarcoma.

Cancers·2026
Same author

Locked-Window EQ-5D-5L (Index and VAS) Benchmarking in Sarcoma Care: Rule-Based Traffic-Light Classification Across Two Institutions.

Diseases (Basel, Switzerland)·2026
Same author

From Network Governance to Real-World-Time Learning: A High-Reliability Operating Model for Rare Cancers.

Cancers·2026

Related Experiment Video

Updated: Jul 7, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.1K

Benchmarking Time-to-Treatment Initiation in Sarcoma Care Using Real-World-Time Data.

Markus Schärer1,2,3, Philip Heesen4, Beata Bode-Lesniewska5

  • 1Sarcoma Service, Department of Orthopaedics and Trauma, University Teaching Hospital LUKS, 6000 Lucerne, Switzerland.

Cancers
|December 23, 2023
PubMed
Summary

Benchmarking sarcoma treatment initiation times reveals a median of 30 days. Optimizing care pathways and specialist referrals can reduce delays for sarcoma patients.

Keywords:
bone-sarcomaintegrated-practice units (IPUs)multidisciplinary team/sarcoma board (MDT/SB)real-world-time data (RWTD)sarcomasoft-tissue-sarcomatime-to-treatment initiation (TTI)value-based healthcare system (VBHCS)

More Related Videos

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.3K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K

Related Experiment Videos

Last Updated: Jul 7, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.1K
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.3K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K

Area of Science:

  • Oncology
  • Healthcare Management
  • Biostatistics

Background:

  • Benchmarking is crucial for quality improvement in patient-centered healthcare.
  • Time-to-treatment initiation (TTI) is a key performance indicator in cancer care.
  • Sarcoma treatment pathways can be complex, necessitating efficient care coordination.

Purpose of the Study:

  • To analyze the time-to-treatment initiation (TTI) for sarcoma patients.
  • To identify factors influencing TTI within a national network.
  • To provide data-driven recommendations for improving sarcoma care timeliness.

Main Methods:

  • Analysis of a retrospective database of 266 sarcoma cases from the Swiss Sarcoma Network.
  • Calculation of median TTI stratified by sarcoma subtype (bone, deep soft tissue, superficial soft tissue).
  • Comparison of TTI using real-world-time data (RWTD) versus conventional datasets.

Main Results:

  • The overall median TTI for sarcoma patients was 30 days.
  • Bone and deep soft tissue sarcomas had a median TTI of 28 days; superficial soft tissue sarcomas had a median TTI of 42 days.
  • Unplanned 'whoops'-resections showed significant delays, highlighting the need for early specialist involvement.

Conclusions:

  • Variability in TTI across institutions necessitates standardized processes.
  • Selective referral to specialized centers and early specialist consultation can optimize sarcoma treatment timelines.
  • Further research into integrated care models is needed to improve TTI and patient outcomes.